1Yamada M, Yasuhara H.Clinical pharmacology of MAO inhibitors: safety and future[J]. Neuroxicology, 2004 ;25( 1,2):215-271.
2O1ie JE Tonnoir B, Menard F, et al. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety[J]. Depress Anxiety. 2007;24(5):318-324.
4Rampello L, Chiechio S, Nicletti G, et al. Prediction of the response to citalopram and reboxetine in poststroke depressed patients[J]. Psychophamacology, 2004; 173(2):73-78.
5Zajecka JM, Albano D.SNRIs in the management of acqte major depressive disorder[J]. J Clic Psychinatry, 2004;65(Suppl 17):11-21.
6Lam RM, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression focus on Meta-analyses[J]. Can J Psychiatry, 2004;49(Suppl 1): 17-26.
7Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatient with major depression[J]. J Affect Disord, 2004;83(2,3):233-236.
8Lynn Wimett, Gary Laustsen. Duloxetine fights major depressive disorder[J]. Nurse Pract, 2005;30(3):6-7.
9Corcoran C, Wong ML, O' Keane V. Bupropion in the management of apathy[J]. Psychopharmacol, 2004; 18(1 ): 133-135.
10Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment resistant depression[J]. J Clin Psychiatry, 2004;65(3):337-340.
9[3]Starkstein SE,Robinson RG,Price TR.Comparison of patients with and without poststroke major depression matched for size and location of lesion[J].Arch Gen Psychiatry,1988,45(3):247～249
10[4]Papp M,Moryl E.Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression[J].Eur J Pharmacol,1994,263(1-2):1～7
